BACKGROUND: The impact of FMS-like tyrosine kinase 3 (FLT3) mutations and mutation burden among cytogenetic subgroups of patients with acute myeloid leukemia (AML) other than normal karyotype (NK) AML is unclear. METHODS: Patients with newly diagnosed AML were divided among 3 cytogenetic subgroups: core binding factor (CBF) AML, NK-AML, and poor-risk AML. RESULTS: In total, 481 patients were included: 13% had, CBF-AML, 57% had NK-AML, and 30% had poor risk AML, and the frequency of any FLT3 mutations was 20%, 32%, and 7.6% in the respective cytogenetic subgroups. FLT3 mutation did not have an impact on event-free survival (EFS) in patients with CBF-AML (P = .84) and poor-risk AML (P = .37). In patients with NK-AML, EFS was worse in the FLT3-internal tandem duplication (ITD) group (20 weeks vs 41 weeks; P < .00,001) but not in the FLT3-tyrosine kinase domain (TKD) point mutation group (61 weeks vs 41 weeks; P = .15). Worse EFS and overall survival (OS) were observed among patients with NK-AML and higher FLT3-ITD burden but not among patients with FLT3-TKD mutation. In multivariate analysis, FLT3-ITD mutation was prognostic of EFS in patients with NK-AML (hazard ratio, 3.1; P = .03). CONCLUSIONS: FLT3 mutations did not have a prognostic impact in patients with AML who had good-risk and poor-risk karyotypes. In patients with NK-AML, FLT3-ITD mutations led to worse survival, which was even worse among patients who had high mutation burden. 2010 American Cancer Society.
BACKGROUND: The impact of FMS-like tyrosine kinase 3 (FLT3) mutations and mutation burden among cytogenetic subgroups of patients with acute myeloid leukemia (AML) other than normal karyotype (NK) AML is unclear. METHODS:Patients with newly diagnosed AML were divided among 3 cytogenetic subgroups: core binding factor (CBF) AML, NK-AML, and poor-risk AML. RESULTS: In total, 481 patients were included: 13% had, CBF-AML, 57% had NK-AML, and 30% had poor risk AML, and the frequency of any FLT3 mutations was 20%, 32%, and 7.6% in the respective cytogenetic subgroups. FLT3 mutation did not have an impact on event-free survival (EFS) in patients with CBF-AML (P = .84) and poor-risk AML (P = .37). In patients with NK-AML, EFS was worse in the FLT3-internal tandem duplication (ITD) group (20 weeks vs 41 weeks; P < .00,001) but not in the FLT3-tyrosine kinase domain (TKD) point mutation group (61 weeks vs 41 weeks; P = .15). Worse EFS and overall survival (OS) were observed among patients with NK-AML and higher FLT3-ITD burden but not among patients with FLT3-TKD mutation. In multivariate analysis, FLT3-ITD mutation was prognostic of EFS in patients with NK-AML (hazard ratio, 3.1; P = .03). CONCLUSIONS:FLT3 mutations did not have a prognostic impact in patients with AML who had good-risk and poor-risk karyotypes. In patients with NK-AML, FLT3-ITD mutations led to worse survival, which was even worse among patients who had high mutation burden. 2010 American Cancer Society.
Authors: Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: D L Stirewalt; K J Kopecky; S Meshinchi; F R Appelbaum; M L Slovak; C L Willman; J P Radich Journal: Blood Date: 2001-06-01 Impact factor: 22.113
Authors: P D Kottaridis; R E Gale; M E Frew; G Harrison; S E Langabeer; A A Belton; H Walker; K Wheatley; D T Bowen; A K Burnett; A H Goldstone; D C Linch Journal: Blood Date: 2001-09-15 Impact factor: 22.113
Authors: R Fenski; K Flesch; S Serve; M Mizuki; E Oelmann; K Kratz-Albers; J Kienast; R Leo; S Schwartz; W E Berdel; H Serve Journal: Br J Haematol Date: 2000-02 Impact factor: 6.998
Authors: Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Maria Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann Journal: Blood Date: 2002-07-01 Impact factor: 22.113
Authors: M-A Hospital; A Jacquel; F Mazed; E Saland; C Larrue; J Mondesir; R Birsen; A S Green; M Lambert; P Sujobert; E-F Gautier; V Salnot; M Le Gall; J Decroocq; L Poulain; N Jacque; M Fontenay; O Kosmider; C Récher; P Auberger; P Mayeux; D Bouscary; J-E Sarry; J Tamburini Journal: Leukemia Date: 2017-09-15 Impact factor: 11.528
Authors: Klaus H Metzeler; Heiko Becker; Kati Maharry; Michael D Radmacher; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield Journal: Blood Date: 2011-10-26 Impact factor: 22.113